PVCT — Provectus Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $40.37m
- $43.21m
- $0.62m
Annual income statement for Provectus Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.989 | 0.558 | 0.617 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.96 | 4.61 | 4.42 | 3.46 | 5.15 |
| Operating Profit | -4.96 | -4.61 | -3.43 | -2.9 | -4.53 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.68 | -5.54 | -3.55 | -3.1 | -4.76 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.68 | -5.54 | -3.55 | -3.1 | -4.76 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.68 | -5.54 | -3.55 | -3.1 | -4.73 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.68 | -5.54 | -3.55 | -3.1 | -4.73 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.016 | -0.012 | -0.007 | -0.006 | -0.01 |